About Us

Andros Pharmaceuticals Co., Ltd. (Andros Pharma) is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. We focus on the development of topical new dosage form and non-viral gene delivery systems, with current pipeline indicated for pain management, DNA repair, and gene therapy.

Our business strategy is to develop unique and competitive new dosage form products of significant market potential, with competitive advantages of our multidisciplinary team, proprietary drug delivery technologies, and a PIC/S GMP certified manufacturing facility. We aim to become a comprehensive drug development company by combining research and manufacturing capabilities.

Andros Pharma was established in July of 2008 at ITRI Incubator center. In consideration of future development and sustainability, Andros Pharma moved to Hsinchu Biomedical Science Park for the expansion of laboratory space and research capacity. In addition to laboratories, the establishment of PIC/s GMP certified manufacturing facility enables Andros Pharma to shorten the product development period, maintain solid quality control, and offer full services of drug development from bench to commercialization. The manufacturing facility was PIC/s GMP certified for cream/gel production in September 2015 and for solution production in March 2016, with maximal output of 80 kg per batch. The facility is designed to support clinical material and commercial productions, as well as sustaining production needs from collaborations and partnerships. Current productions of super generics allow Andros Pharma to increase facility availability and generate cashflow.

Innovation and quality are highly held core values at Andros Pharma. "Where there is a will, there is a way" is the allusion of the name of Andros Pharma in Chinese to express the attitude for pursuing a high quality and state of mind. We strive to utilize innovative drug delivery technologies to develop new dosage form products of highest standard, and deliver them to patients worldwide to improve life quality.

Improve well-being of the people by delivering high quality technologies and products.

Become a global leader in innovative drug delivery technologies, with comprehensive product development process.

The company has been listed on the Emerging Stock Board (ESB) of the Taipei Exchange on January 12, 2023.

For related information, please refer to TWSE Market Observation Post System: https://mops.twse.com.tw/mops/web/index
Stock symbol: 6917